troglitazone has been researched along with Adenocarcinoma of Lung in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Adenocarcinoma of Lung: A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tsujiya, Y | 1 |
| Hasegawa, A | 1 |
| Yamamori, M | 1 |
| Okamura, N | 1 |
1 other study available for troglitazone and Adenocarcinoma of Lung
| Article | Year |
|---|---|
Troglitazone-Induced Autophagic Cytotoxicity in Lung Adenocarcinoma Cell Lines.
Topics: Adenocarcinoma of Lung; Apoptosis; Autophagy; Cell Line; Cell Line, Tumor; Cell Proliferation; Chrom | 2022 |